The cost-effectiveness of the ProbeTec ET Direct TB assay (DTB) was compared with that of culture for detection of Mycobacterium tuberculosis complex in 361 acid-fast stain-positive respiratory specimens. The overall sensitivity, specificity, positive predictive value and negative predictive value of DTB were 97.7%, 86.6%, 87.2% and 97.6%, respectively. When clinical evaluation was added to DTB, the specificity and positive predictive value of DTB increased to 94.7% and 95.4%, respectively. Treatment costs of $133 521 would have been saved in this cohort if DTB, instead of culture results, had been used to eliminate 'false-positive' smear results. Abstract As a novel antibiotic resistance determinant, investigation of the occurrence and characteristics of class 1 integron was performed on nosocomial methicillin-resistant Staphylococcus aureus (MRSA) strains sampled during 2001-2006. Seventy-six out of 179 (42.5%) of the tested strains were found to carry class 1 integrons, with four unique arrays of gene cassettes detected. This is the first report of the comprehensive identification and typing of class 1 integrons in clinical MRSA isolates over a 6-year period, representing the first evidence for class 1 integrons as possible antibiotic resistance determinants in clinical MRSA strains.
Initial screening for active pulmonary tuberculosis (TB) is usually performed by staining for acid-fast bacilli (AFB), but this fast and inexpensive test cannot distinguish Mycobacterium tuberculosis complex (MTB) from non-tuberculosis mycobacteria (NTM) [1, 2] . To protect the public from the possible spread of this very contagious disease, patients with 'false-positive' stains are treated with antibiotics until sputum culture demonstrates the absence of MTB, a period of 3-6 weeks. A reliable and rapid method for eliminating 'false-positive' AFB smear results would decrease the financial burden on the healthcare system and the adverse effects on patients of receiving unnecessary antibiotic treatment while awaiting sputum culture results.
The ProbeTec ET direct TB assay (DTB; Mycobacterium tuberculosis complex TB Direct Detection Assay; Becton Dickinson, Sparks, MD, USA) for the detection of MTB is highly specific and time-saving [3] [4] [5] [6] . It is sensitive when used to verify AFB-positive smear results, and can thus be used for early detection of TB cases [7] . The objective of this study was to assess the reliability DTB in detecting TB cases among AFB-positive specimens, and to determine the potential cost saving in patient care resulting from the use of this assay.
Three hundred and sixty-one AFB-positive respiratory secretion specimens from 325 patients with symptoms of pneumonia or pulmonary TB were collected at Kaohsiung Veterans General Hospital and used for DTB and culture. If the patients had more than one set of AFB-positive samples within 3 months, we selected only one set to detect TB with the DTB. All patients provided informed consent. Clinical procedures were approved by our institutional review board.
Smears were stained with Kinyoun acid-fast stain. AFB counts were defined as follows: 'not found,' 0/300 field; 'doubtful,' 1-2/300 field; AFB 1+, 1-9/100 field; AFB 2+, 1-9/ 10 field; AFB 3+, 1-9/field; AFB 4+, >9/field [8, 9] . Culture at 35°C for 6 and 8 weeks was performed as previously described [9, 10] .
DTB on AFB-positive specimens was performed weekly, according to the manufacturer's instructions [11] .
Clinical evaluation included granulomatous inflammation with or without caseous necrosis in a lung or lymph node biopsy specimen, predominant upper lobe infiltrates, cavitation or miliary patterns in chest radiographs, AFB detected in histopathological studies of excisional biopsy specimens, and favourable anti-TB treatment.
Calculation of the total cost, including the costs of antibiotics, isolation ward, medicines service, doctor consultations (including chest X-ray, sputum smears and cultures) and other related expenses, was performed for the positive AFB stain cohort [12] . Specimens were analysed by using a count and percentage for categorical variables. Kappa analysis was used to assess interobserver agreement between DTB and culture results.
It was found that 54.3% (196/361) of DTB results and 48.5% (175/361) of culture results for AFB-positive smears were positive (Table 1) . A small fraction of DTB results were inconclusive, because of the presence of inhibitory substances (3.3%, 12/361), but, unlike acid-fast staining, DTB clearly distinguished between tuberculous mycobacteria and NTM.
When compared with culture results alone, DTB showed a sensitivity of 97.7%, a specificity of 86.6%, a positive predictive value of 87.2% and a negative predictive value of 97.6%. However, 16 patients with negative culture results (seven with no bacterial growth, four with contamination, and five with NTM) were diagnosed with TB by clinical evaluation. If we defined positive TB cases according to both clinical evaluation and culture results, the sensitivity and specificity of the DTB assay increased to 97.9% and 94.7%, the positive and negative predictive values were 95.4% and 97.6%, and the kappa value was 0.93.
In Taiwan, current guidelines are that symptomatic patients should immediately receive anti-TB therapy for 14 days in an isolation ward if one or more specimens are AFB-positive. Forty-four per cent (71/161) of the 'falsepositive' smear patients were treated as outpatients, and 56% (90/161) as inpatients; the latter were transferred to the isolation ward for 14 days of therapy. All were treated with antituberculosis drugs (average of 35.6 days/patient) until culture results were available ( Table 2 ). The total cost was US$1771.5 for a hospitalized patient found to be TB-negative by culture, but only $330.3 for a patient found to be TB-negative by DTB. The total cost for an outpatient was $85.3 if false positives were eliminated through culture and $31.3 if they were eliminated by DTB. Hence, substituting DTB for culture saved $1441.2 per hospitalized patient and $54 per outpatient case. In the cohort described here, in which 56% were treated as hospitalized patients and 44% as outpatients, a total saving of US$133 521 saving would have been made if DTB had been used to eliminate all 'false positives' ( Table 2 ).
The major advantage of DTB over culture for the identification of positive smears for TB is that DTB takes 4 h instead of the 3-6 weeks necessary for culture.
DTB is a rapid technique for identification of the M. tuberculosis complex directly from AFB-positive clinical specimens. Its negative predictive power in this study is 97.6%, a result that is similar to that of others [7] , and its sensitivity is over 95%. Although DTB costs more than culture, it can reduce $) 133 521 a The cost of antimicrobial therapy for tuberculosis for 14 days in the isolation ward per patient was US$21. The average number of days before culture-negative results were confirmed was 35.6, so outpatient antibiotic therapy was continued for 21.6 days, at a cost of US$180.8.
costs by reducing unnecessary hospitalization and medication for patients with 'false-positive' initial AFB smears.
